EULAR 2018

Nonmedical Switching in Rheumatic Disease: An Interview With Allan Gibofsky, MD

Nonmedical Switching in Rheumatic Disease: An Interview With Allan Gibofsky, MD

By

Allan Gibofsky, MD, shares insight on the cost associated with nonmedical switching in patients with rheumatic diseases.

Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

By

In biologic-naive patients with psoriatic arthritis who are treated with apremilast, early onset of effect was observed across disease PsA manifestations.

Sprifermin Improved Cartilage Morphology, Thickness in Knee Osteoarthritis

Sprifermin Improved Cartilage Morphology, Thickness in Knee Osteoarthritis

By

Sprifermin has a positive effect on cartilage morphology and cartilage thickness in radiographic knee osteoarthritis.

Allopurinol Medication Adherence Increased With Daily Text Message Reminders

Allopurinol Medication Adherence Increased With Daily Text Message Reminders

By

Mobile phone text reminders could be an important tool to enhance medication adherence in people with gout.

Depressive Symptom Onset Linked to Disease Severity in Knee OA

Depressive Symptom Onset Linked to Disease Severity in Knee OA

By

To effectively treat individuals with radiographic knee OA and comorbid depressive disorder, it is necessary to use a combined treatment strategy of 2 interventions delivered in parallel to simultaneously target each condition.

Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

By

The objective of this cross-sectional analysis was to evaluate the prevalence of osteoporosis and frequency of fractures in patients with psoriasis or psoriatic arthritis.

Low Tuberculosis Screening Rates Observed Among Patients Starting TNFis

Low Tuberculosis Screening Rates Observed Among Patients Starting TNFis

By

Only about half of patients who started TNFi therapy were screened for tuberculosis prior to therapy initiation.

Optical Fiber Infrared Spectroscopy Identifies Septic vs Nonseptic Synovial Fluids

Optical Fiber Infrared Spectroscopy Identifies Septic vs Nonseptic Synovial Fluids

By

Researchers sought to confirm the interest of mid-infrared spectroscopy to discriminate synovial fluid samples from patients with septic arthritis from other causes of joint effusion.

RA Associated With Greater Reduction in Short-Term Disease Burden vs Osteoarthritis

RA Associated With Greater Reduction in Short-Term Disease Burden vs Osteoarthritis

By

Investigators analyzed MDHAQ/RAPID3 scores in patients with osteoarthritis or rheumatoid arthritis to assess disease burden associated with each rheumatic disease.

SLE-DAS Superior to SLEDAI-2K in Detecting Changes in SLE Disease Activity

SLE-DAS Superior to SLEDAI-2K in Detecting Changes in SLE Disease Activity

By

To assess validity of SLE-DAS, investigators performed a Spearman's correlation between SLE-DAS, PGA, and SLEDAI-2K at the last follow-up visit.

Infliximab May Lower Glucocorticoid Requirements, Lead to Remission in Takayasu Arteritis

Infliximab May Lower Glucocorticoid Requirements, Lead to Remission in Takayasu Arteritis

By

Treatment of active Takayasu arteritis with infliximab may result in remission or in a diminished requirement for glucocorticoids.

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

By

Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.

Zoledronic Acid May Not Improve Knee Osteoarthritis-Related Pain, Function Long-Term

Zoledronic Acid May Not Improve Knee Osteoarthritis-Related Pain, Function Long-Term

By

Zoledronic acid did not significantly reduce knee pain or bone marrow lesion size overall in patients with knee osteoarthritis over 24 months.

NSAID Use Mediates CVD Risk in Osteoarthritis

NSAID Use Mediates CVD Risk in Osteoarthritis

By

Nonsteroidal anti-inflammatory drug use mediated a substantial amount of cardiovascular disease risk in osteoarthritis.

Cardiac Screening May Not Be Beneficial in SLE With Anti-Ro Antibodies

Cardiac Screening May Not Be Beneficial in SLE With Anti-Ro Antibodies

By

Cardiac screening in patients with systemic lupus erythematosus and anti-Ro-positive antibodies does not appear to be beneficial in clinical practice.

RA: Psychological State Predicts Disease Flare Following TNF Tapering

RA: Psychological State Predicts Disease Flare Following TNF Tapering

By

Based on these results, clinicians should consider assessing functional and mental health states before biologic tapering.

Effects of Maternal axSpA Disease Activity on Pregnancy Outcomes Examined

Effects of Maternal axSpA Disease Activity on Pregnancy Outcomes Examined

By

A systematic review revealed no signal for increased pregnancy loss in patients with axial spondyloarthritis.

Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis

Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis

By

Tofacitinib may provide a fast and prolonged analgesic effect in patients with rheumatoid arthritis or psoriatic arthritis who are unresponsive to csDMARD or to TNFi, as well as in individuals with ankylosing spondylitis.

Ustekinumab, TNF Inhibitors Improve 6-Month Outcomes in Psoriatic Arthritis

Ustekinumab, TNF Inhibitors Improve 6-Month Outcomes in Psoriatic Arthritis

By

Researchers sought to evaluate the efficacy, tolerability, and persistence of TNFi and ustekinumab in patients with psoriatic arthritis initiating first-line, second-line, or third-line biologic DMARDs.

Baricitinib Shows Positive Results for Systemic Lupus Erythematosus in Phase 2 Study

Baricitinib Shows Positive Results for Systemic Lupus Erythematosus in Phase 2 Study

By

Baricitinib 4 mg was safe and effective in patients with systemic lupus erythematosus.

Determining Elevated Thrombotic Risk in Systemic Lupus Erythematosus

Determining Elevated Thrombotic Risk in Systemic Lupus Erythematosus

By

Recent data from EULAR 2018 highlight the existence of thrombotic factors in systemic lupus erythematosus.

RA: MRI Values May Not Benefit Clinical, Radiographic Outcomes in Treat-to-Target Strategy

RA: MRI Values May Not Benefit Clinical, Radiographic Outcomes in Treat-to-Target Strategy

By

Researchers sought to determine whether a treat-to-target strategy based on MRI assessments targeting absence bone marrow edema would lead to improved clinical and radiographic outcomes.

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

By

There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.

Obesity May Not Be Associated With Development of Lupus Nephritis

Obesity May Not Be Associated With Development of Lupus Nephritis

By

Obesity is not associated with the development of lupus nephritis among patients with systemic lupus erythematosus.

Bimekizumab Linked to 12-Week Clinical Improvements in Ankylosing Spondylitis

Bimekizumab Linked to 12-Week Clinical Improvements in Ankylosing Spondylitis

By

Investigators assessed the 12-week efficacy and safety of bimekizumab in patients with active ankylosing spondylitis.

Sign Up for Free e-newsletters